Infant synbiotics Leverage Persephone’s newly launched infant and toddler synbiotics to target retailers, pediatric clinics, and family-focused e-commerce platforms seeking science-backed gut and immune health solutions for young children.

Clinical collaboration Explore partnerships with hospitals, clinical trial networks, and health systems (notably those connected to ARGONAUT and colorectal cancer biomarker studies) to expand access to Persephone’s microbiome-based therapeutics and to co-develop data-driven outcomes.

Retail & e-comm Capitalize on availability on Amazon and direct-to-consumer potential by offering bundled probiotic synbiotics with education resources, enabling mass-market reach to health-conscious parents and caregivers.

Strategic partnerships Build on past collaborations with Kroger and Janssen by pursuing additional health-system pilots, pharmacy partnerships, and consumer health distribution channels to scale adoption of microbiome-focused products.

Data-driven growth Position Persephone as a data-backed microbiome leader by highlighting the My Baby Biome study and synbiotic clinical research to attract investor interest, grant opportunities, and enterprise customers seeking proven health outcomes.